Research Progress on the Treatment of Premature Ovarian Failure Using Mesenchymal Stem Cells: A Literature Review

Jing Wang1, Wanru Liu1, Dehai Yu2, Zongxing Yang3, Sijie Li4 and Xiguang Sun5*

1Department of Reproductive Medicine, Department of Prenatal Diagnosis, The First Hospital of Jilin University, Changchun, China, 2The Laboratory of Cancer Precision Medicine, The First Hospital of Jilin University, Changchun, China, 3Department of Clinical Laboratory, The First Hospital of Jilin University, Changchun, China, 4Department of Breast Surgery, The First Hospital of Jilin University, Changchun, China, 5Hand Surgery Department, The First Hospital of Jilin University, Changchun, China

Premature ovarian failure (POF) has become one of the main causes of infertility in women of childbearing age and the incidence of POF is increasing year by year, seriously affecting the physical and mental health of patients and increasing the economic burden on families and society as a whole. The etiology and pathogenesis of POF are complex and not very clear at present. Currently, hormone replacement therapy is mainly used to improve the symptoms of low estrogen, but cannot fundamentally solve the fertility problem. In recent years, stem cell (SC) transplantation has become one of the research hotspots in the treatment of POF. The results from animal experiments bring hope for the recovery of ovarian function and fertility in patients with POF. In this article, we searched the published literature between 2000 and 2020 from the PubMed database (https://pubmed.ncbi.nlm.nih.gov), and summarized the preclinical research data and possible therapeutic mechanism of mesenchymal stem cells (MSCs) in the treatment of POF. Our aim is to provide useful information for understanding POF and reference for follow-up research and treatment of POF.

Keywords: mesenchymal stem cells, fertility, premature ovarian failure (POF), ovarian dysfunction, reproductive medicine

INTRODUCTION

POF is a kind of ovarian dysfunction characterized by menstrual disorder, ovarian atrophy, decreased sexual life and decreased fertility in women between puberty and 40 years old, which seriously affects female reproductive health and endocrine balance and is one of the main causes of female infertility (Sheikhansari et al., 2018). Approximately 1% of women under the age of 40 suffer from premature ovarian failure (Huhtaniemi et al., 2018). Under the influence of high pressure and a fast paced life, the incidence of POF is increasing and manifesting at younger ages, and it has affected more than 10% of women in recent years (Thakur et al., 2018).

POF treatment is extremely difficult. Although assisted reproductive technology has become an effective treatment, it is not ideal, and fertility loss and low estrogen status have become a great threat to female reproductive health (Laven, 2016). POF has become one of the most severe problems threatening the reproductive health of women of normal childbearing age. Its occurrence may be related to an insufficient reserve of primordial follicular cistern, accelerated follicular atresia, changes...
of dominant follicular recruitment, follicular maturation disorders and so on (Xiang et al., 2019). In view of the limitations of conventional treatment, clinical and scientific research work has focused on improving ovarian function and restoring fertility in patients with POF. In recent years, MSC transplantation has opened up a new direction for the treatment of POF, but this is still in the stage of preclinical research (Lai et al., 2015; Sun et al., 2017; Zhang et al., 2018; Liu S. et al., 2019; Zheng et al., 2019), and there are few clinical studies so far. The mechanism by which MSCs improve ovarian function has also not been completely elucidated. At present, there is no clear and effective treatment to restore the reproductive function of ovaries. In this paper, we reviewed the preclinical research data of the treatment of POF using MSCs and the possible therapeutic mechanisms to provide a reference for follow-up research and treatment of POF.

THE CURRENT SITUATION OF POF TREATMENT

POF is a reproductive endocrine disease that occurs before the age of 40 and is characterized by increased gonadotropin levels and decreased estrogen levels, accompanied by primary or secondary amenorrhea. It is also one of the common diseases leading to female infertility. POF is a highly heterogeneous condition. Abnormal follicular development in all stages can lead to POF, and such damage to ovarian function is irreversible. The pathogenic factors of POF include heredity, autoimmunity, viral infection, iatrogenic factors, and environmental and psychological factors, and approximately eighty percent of POF cases are idiopathic (Webber et al., 2016) (Figure 1A). It has been reported that radiotherapy, chemotherapy and bone marrow transplantation of cancer can result in POF (Dolmans and Donnez, 2021; Imai et al., 2008). The traditional treatment of POF includes hormone replacement therapy (HRT), psychological support therapy, androgen-dependent therapy, biocorticoid-dependent therapy, dehydroepiandrosterone therapy and puberty induction (Figure 1B). However, HRT can only relieve low estrogen symptoms such as vaginal dryness, hot flashes and genitourinary tract atrophy, but has no essential effect on improving ovarian reproductive function. Long-term use of HRT is controversial because it increases the risk of endometrial and ovarian cancer (Ali, 2013; Lee et al., 2020). Since the etiology of POF infertility is complex, the current treatment efficacy is unsatisfactory, and the pregnancy rate and carrying to term rates are still quite low after treatments. Therefore, for women with fertility requirements, it is necessary to strengthen early prevention, early detection and early treatment to delay the development of POF and improve the live birth rate.

The results from animal experiments of MSC transplantation has brought hope to the recovery of ovarian function and fertility in patients with POF. In the following, we will introduce advances in the treatment of POF with MSCs.

MSCS AND FERTILITY PROTECTION

MSCs were the first type of adult stem cell discovered in bone marrow. They originate from mesoderm and are distributed in almost all connective tissue and organ stroma of the entire body. They have the potential for multidirectional differentiation of stem cells and also have a strong migration ability to damaged tissues. Since MSCs have low immunogenicity and fewer disputes in bioethics than fetal-derived stem cells, they are widely applied in clinical research and medical bioengineering (Pers et al., 2016; Badawy et al., 2017; Mu et al., 2018). Currently, MSCs have been used to treat diseases related to the blood, nervous, motor, cardiovascular and skin systems, showing good curative effects (Zaher et al., 2014). The reproductive capacity of most female mammals is mainly affected by the primordial follicular pool. Under normal
| Research category | Type of MSCs | Method | Outcome of MSC treatment | Molecular mechanism | Biological effect | References |
|-------------------|--------------|--------|--------------------------|---------------------|------------------|------------|
| Preclinical research/animal experiment | Mouse menSCs | Injection by the tail vein | Repairing ovarian injury, improving ovarian function and stimulating regeneration | MenSCs produce high level of PGF2, which is essential for angiogenesis and the proliferation and remodeling of endometrial cells that plays important roles in repairing and regenerating the damaged tissues | MenSCs increase the follicular numbers, return sex hormone level, repair oocyte function and protect ovary damage | Wang et al. (2017) |
| Preclinical research/animal experiment | Human PMSCs | Injected subcutaneously | Restoring ovarian function | PMSCs activate the PI3K/Akt pathway, reduce Th17 cells percentage and increase Treg cells percentage | PMSCs increase serum levels of E2 and AMH and decrease FSH, LH and A2PAb levels | Yin et al. (2018b) |
| Preclinical research/animal experiment | Human AMSCs | Intraperitoneal injection and intragastric administration | Improving injured ovarian tissue structure and function | AMSC transplantation elevate serum oestrogen level and decrease FSH secretions | AMSCs promote follicular development, granulosa cell proliferation and secretion function by improving the local microenvironment of POF, mouse ovary | Liu et al. (2019b) |
| Preclinical research/animal experiment | Mouse ADSCs | Intravenous injection | Improving ovarian function | Expression levels of ZCCHC11, ANGPTL and ONECUT2 are upregulated | MSC conditioned media stimulates the proliferation of HOVEC cells | Sun et al. (2013) |
| Preclinical research/laboratory research | Human BMSCs | Collection of MSC conditioned media | — | BMSCs conditioned media increase angiogenesis marker including VEGF, VEGFR, Endoglin, Tie-2 and VE-Cadherin through the PI3K/ALK pathway | — | Park et al. (2019) |
| Preclinical research/animal experiment | Human BMSCs | Intraovarian injection | Restoring ovarian hormone production and reactivating folliculogenesis | BMSCs decrease FSH level and increase AMH level | BMSCs induce follicle growth and increase the pregnancy rate | Mohamed et al. (2018) |
| Preclinical research/animal experiment | Human UCMSC | Intraovarian injection | UCMSC transplantation preserved ovarian function of POF mice | UCMSC transplantation increase estrogen (E2) and AMH levels, and increase the expression of CD31 | UCMSCs increase ovarian volume and the number of antral follicles, and promote granulosa cell proliferation and ovarian angiogenesis | Yang et al. (2019b) |
| Clinical research | Human UCMSC | Intraovarian injection | Two POF patients conceived naturally within 1 year after UCMSC transplantation | UCMSCs activate primordial follicles via phosphorylation of FOXO3a and FOXO1 | UCMSCs rescue ovarian function, elevate estradiol concentrations, improve follicular development and increase the number of antral follicles | Ding et al. (2018) |
| Clinical research | Human autologous BMSC | Laparoscopic intraovarian injection | BMSC treatment revealed promising improvement of POF. | — | BMSCs elevate serum estrogen level, increase volume of the treated ovaries and improve menopausal symptoms | Igboeli et al. (2020) |
| Clinical research | Human autologous BMSC | Laparoscopic intraovarian injection | — | BMSCs increase AMH level | BMSCs improve follicular development | Gupta et al. (2018) |
| Clinical research | Human autologous BMSC | Laparoscopic intraovarian injection | Perimenopausal woman delivered a healthy baby 5/15 poor responders conceived and 3 healthy babies were born after the stem cell administration | BMSCs increase AMH level and antral follicular count | BMSCs increase the number of antral follicles and retrieve oocytes | Herraiz et al. (2018) |
| Clinical research | Human autologous ADSCs | Intraovarian injection | Menstruation resumption | BMSCs decreased FSH level | — | Mashayekhi et al. (2021) |
| Clinical research | Human autologous UCMSC | Intraovarian injection | UCMSC transplantation improved the injured ovarian function, and 4/61 POI patients obtained clinical delivery | — | UCMSCs increase follicular development and improve egg collection | Yan et al. (2020) |
circumstances, to avoid depletion of the follicular pool, most primordial follicles in the ovary are maintained in a resting phase. Primordial follicles undergo follicular activation and a series of developmental processes and finally develop into mature follicles. Various molecules are involved in regulating follicular activation, growth and atresia. Ovarian function recovery is based on oocyte developmental processes and the maintains in a resting phase. Primordial follicles undergo follicular activation and a series of developmental stages; 3) MSCs may induce and differentiate into primordial germ cells (uncertain); 4) MSCs can directly differentiate into GCs or inhibit the apoptosis of GCs; 5) MSCs can promote the formation of ovarian blood vessels; 6) MSCs have immunomodulatory and anti-inflammatory effects and 7) MSCs can reduce oxidative stress.

**Homing Effect of MSCs**

The homing capacity of MSCs is an important determinant of effective MSC-based therapy (Li et al., 2017; Lin et al., 2017). Homing refers to the process by which MSCs migrate to damaged tissues and promote their recovery. Therefore, enhancing the homing efficiency of MSCs is essential for optimizing the therapeutic outcome of POF. Noory et al. reported the application of MenSC transplantation as a treatment modality in a rat model of POF and observed that MSCs can survive in ovarian stroma at 2 months after MSC transplantation and directly differentiated into GCs (Noory et al., 2019). Experiments from Liu et al., Jalalie, Lai et al., Song et al. and Park et al. also demonstrated that after transplantation, MSCs home to damaged tissue and reach the site of injured ovaries (Liu et al., 2014; Lai et al., 2015; Jalalie et al., 2019; Park et al., 2021). However, studies have also shown that although MSCs have a homing effect, they cannot directly differentiate into oocytes but do localize in the ovarian matrix, secrete various cytokines and improve ovarian reserve function through the paracrine pathway (Takehara et al., 2013; Gabr et al., 2016; Li et al., 2016; Li et al., 2017). A study by Taheri et al. demonstrated that MSC isolated from follicular fluid cultured in human recombinant BMP15 medium may differentiate into oocyte-like cells in vitro, but they did not investigate whether such MSCs can differentiate into oocytes in vivo (Taheri et al., 2021). Therefore, whether MSCs can directly differentiate into oocytes remains unclear, and more in-depth laboratory experiments are still necessary to solve this scientific problem.

**Effects of MSCs on Follicular Development**

Folliculogenesis is an important part of ovarian function, as it provides oocytes for reproduction (Hua et al., 2015). A large number of genes/proteins have been identified to be associated with follicular development, growth, ovulation and atresia processes. It has been reported that PMSC transplantation can increase the secretion of growth factors, angiogenic factors, pleiotropic cytokines, chemotactic cytokines and extracellular matrix proteins, which are all essential for folliculogenesis (Kupcova Skalnikova, 2013). In POF treatment, the widely discussed follicular development related genes are Nanos3, Nobox and Lhx8. Lai et al. proved that SMSC transplantation could reactivate injured mouse ovaries, with increased expression of the folliculogenesis marker genes Nobox, Nanos3, and Lhx8 in the ovaries of SMSC-treated mice (Lai et al., 2014). Kim et al. showed that three-dimensional cultured PDMSC spheres could upregulate the expression level of Nanos3, Nobox and Lhx8, and resume ovulation through regulation of the follicular microenvironment and stimulation of follicular development (Kim et al., 2018). Peng et al. also showed that the mRNA levels of these three genes in POF mice treated with BMSCs...
were significantly higher than those in the untreated group (Peng et al., 2018). Other follicular development-related genes include Foxo3a and Foxo1. Ding et al. found that UCMSCs on a collagen scaffold can activate primordial follicles in vitro via phosphorylation of FOXO3a and FOXO1, and transplantation of collagen/UCMSCs to the ovaries of POF patients can elevate estradiol concentrations, improve follicular development and increase the number of antral follicles (Ding et al., 2018).

Cytokines are critical regulators of folliculogenesis and ovulation. They contribute to creating an environment supporting follicle selection and growth, regulating cellular proliferation/differentiation, follicular survival/atrophy and oocyte maturation (Field et al., 2014). The most important cytokines in POF treatments are TGF-β and IFN-γ. TGF-β superfamily members, including TGF-βs, AMH, activins, inhibins, BMPs and GDFs, impact several stages of follicular development (Trombly et al., 2009; Sanfins et al., 2018). According to Knight et al., the positive TGF-β regulators of preantral follicle growth, include GDF-9 and BMP-15 of oocyte origin, activins of granulosal origin, BMP-4 and BMP-7 of thecal origin and TGF-β from theca and GCs; in contrast, AMH plays a negative role in preantral follicle development (Knight and Glisten, 2006). However, the existing research conclusions are not consistent with each other. El-Derany et al. transplanted BMSCs to a γ-ray induced POF rats model and reported that BMSCs recovered the folliculogenesis process, upregulating Foxo1, Gdf-9 and Fst gene expression accompanied by downregulating TGF-β (El-Derany et al., 2021), whereas Song et al. and Yin et al. found that MSC transplantation could increase the level of TGF-β and decrease the level of IFN-γ in POF models (Yin et al., 2018a; Song et al., 2018). Additionally, Ling et al. reported that amnion-derived mesenchymal stem cell transplantation can inhibit granulosa cell apoptosis and that the expression levels of AMH were significantly increased in the treatment group compared to the POF group (Ling et al., 2017). Zhang et al. and Mohamed et al. also found that after MSC transplantation, AMH expression in ovarian tissue was significantly higher than that in the POF group (Mohamed et al., 2018; Zhang et al., 2018).

Although the mechanism of MSCs on follicular development is not completely clear, most research agrees that MSC transplantation can promote the development and formation of primordial follicles, eggs and reduce the apoptosis of GCs. All of the involved genes and their correlated mechanisms are listed in Table 2.
MSCs and PGCs

Multiple studies have shown that MSCs can be induced and differentiate into PGCs. Fang et al. and Li et al. proved that CD61 could promote the differentiation of ADMSC into PGC-like cells through activation of the TGF-β pathway (Li et al., 2016; Fang et al., 2017). Wei et al. found that AMSC can be induced into PGC-like cells by BMP4 (Wei et al., 2016). Ge et al. found that when hiSDSCs were cultured in porcine follicle fluid, they may differentiate into both male and female germ cell-like cells (Ge et al., 2015). Park et al. proved that female mouse skin-derived stem cells could differentiate into ovarian-cell-like cells that are consistent with female germ, and ovarian follicle somatic cells. When ovarian cell-like cells are transplanted into ovariectomized mice, they restore the estrus cycle and serum estradiol levels (Park et al., 2014). Unfortunately, no in vivo research has reported whether MSC-differentiated germ cells can be fertilized and form embryos, and studies in this area are still lacking.

MSCs Can Promote the Proliferation of GCs

OGCs are the most important stromal cells in the ovary, providing necessary nutrition for oocyte development and follicle maturation, participating in the regulation of gonadotropins that modulate oocyte development and maintaining the microenvironment of oocyte maturation through autocrine and paracrine mechanisms. GCs play an important role in all developmental stages of follicles. GCs abnormalities can lead to abnormal hormone secretion, follicular development disorders and even follicular atresia (Lai et al., 2014). Chemotherapy induces GC apoptosis by damaging DNA and activating apoptosis pathways, thus leading POF. Therefore, enhancing GC function and inhibiting GC apoptosis may effectively prevent POF (Bedoschi et al., 2016). Studies have shown that GCs and MSCs express some similar surface markers (Dzaifci et al., 2014; Maleki et al., 2014). Transplanted MSCs are mainly located in the GC layer around follicles, suggesting that MSCs have a significant effect on follicle formation and ovulation (Manshadi et al., 2019).

MSCs can inhibit GC apoptosis and promote GC proliferation by releasing cytokines and hormones, upregulating proliferation-related genes and inhibiting apoptosis-related genes (He et al., 2018; Wang et al., 2020). Zhang et al. showed that BMSC transplantation could upregulate the expression of AMH and FSHR in GCs of POF mice, inhibit GC apoptosis and follicular atresia, and thus restore ovarian function (Zhang et al., 2018). Fu et al. also found that BMSC transplantation may reduce GC apoptosis and improve ovarian function by releasing VEGF, HGF, and IGF-1 and upregulating Bcl-2 expression (Fu et al., 2008). Ding et al. showed that coculturing of AMSCs and GCs might inhibit the apoptosis of GCs, and transplantation of AMSCs may improve ovarian function during natural aging by secreting HGF and EGF (Ding et al., 2018).

The underlying mechanism of MSC treatment of POF may be related to exosome-mediated microRNA modulation. Multiple studies have highlighted the potential therapeutic advantages of using exosomal miRNAs from MSCs for the treatment of various diseases and injuries, including POF. Yang et al. demonstrated that BMSC-derived exosomes prevent ovarian follicular atresia in POF rats via the delivery of miR-144-5p, which can decrease GC apoptosis by targeting the PTEN pathway (Yang et al., 2020). Xiao et al. found that miR-146a and miR-10a are rich in exosomes secreted by AFSCs. miR-146a can restore ovarian function by downregulating IRAK1 and TRAF632 expression and miR-10a can inhibit GC apoptosis and prevent follicular atresia by suppressing Bim and caspase-9 expression (Xiao et al., 2016). Sun et al. found that exosomes derived from UCMSCs may prevent and treat chemotherapy-induced OGC apoptosis in vitro by upregulating the expression level of Bcl-2 and downregulating the expression levels of caspase-3, Bax, cleaved

**TABLE 2 | The effects of MSCs on follicular development.**

| Related gene/hormones/ cytokines | Regulation of expression | Outcome of MSC treatment | References |
|----------------------------------|--------------------------|--------------------------|------------|
| Nanos3                           | Up                       | Reducing atretic follicle and increasing antral follicle and secondary follicle | Lai et al. (2014) |
| Nobox                            | Up                       | Reducing atretic follicle and increasing antral follicle and secondary follicle | Lai et al. (2014) |
| Lhx8                             | Up                       | Stimulating follicular development and resuming ovulation | Kim et al. (2018) |
| TGF-β                            | Up                       | Inhibiting follicular atresia and reducing the apoptosis of GCs in secondary follicles and cystic follicles | Knight and Glister (2006) |
| IFN-γ                            | Down                     | Recovering the suppressed folliculogenesis process and promoting egg formation | El-Derany et al. (2021) |
| AMH                              | Up                       | Promoting follicular growth | Song et al. (2018) |
| AMH                              | Up                       | Inhibiting granulosa cell apoptosis | Zhao et al. (2018a) |
| FOXO3a                           | Up                       | Increasing the number of follicles | Ling et al. (2017) |
| FOXO1                            | Up                       | Promoting follicular growth | Mohamed et al. (2018) |
| FOXO1                            | Up                       | Promoting follicular development and maturation | Ding et al. (2018) |
MSCs Promote Angiogenesis

The establishment and remodeling of the ovarian vascular system is the basis of ovarian development and functional recovery. The follicles and corpus luteum can obtain nutritional support through ovarian blood vessels and transport hormones to target organs. Some researchers observed the distribution of BMSCs in ovaries by labeling specific markers of BMSCs and found that BMSCs were mainly distributed in the blood vessels of damaged ovaries (Liu et al., 2014), implying that BMSCs may play a role in ovarian blood vessels construction. Angiogenesis-related factors secreted by MSCs, such as VEGF, HGF, IGF and FGF, are increased in MSC-transplanted POF ovaries. VEGF and HGF have a synergistic effect and synergistically promote angiogenesis (Golocheikine et al., 2010). The combination of VEGF and HGF leads to an increased vascular diameter (Bellmann et al., 2004); VEGF promotes the length, area and branch point number of the induced vessels, while HGF contributes to vascular area growth (He et al., 2018). Wang et al. showed that MSCs could promote ovarian angiogenesis and reduce interstitial fibrosis by secreting VEGF, IGF-1, GCSF and HGF (Wang et al., 2017). Xia et al. demonstrated that MSC transplantation could enhance the expression levels of VEGF, FGF2 and angiogenin, significantly stimulate neovascularization and increase blood perfusion of the grafts in ovarian tissue (Xia et al., 2015). Zhang et al., Cho et al. and Park et al., also proved that MSC transplantation could repair damaged POF ovaries and promote ovarian development and function through angiogenesis (Zhang et al., 2017; Park et al., 2019; Cho et al., 2021).

Microvesicles are cell-derived membrane and cytoplasmic components. There are three subtypes of EVs: exosomes, microvesicles and apoptotic bodies. Exosomes and microvesicles can transfer mRNA, protein and lipids to target cells through surface-expressed ligands and surface receptors, thus affecting the phenotype and function of the target cells (Bidarimath et al., 2017). EVs have a therapeutic effect on female reproductive disorders, such as repairing injured endometrium, suppressing fibrosis of the endometrium, regulating immunity and anti-inflammation, and repressing the apoptosis of GCs in ovaries (Liao et al., 2021). Several studies have shown that MSC-derived microvesicles contain multiple pro-angiogenic proteins, such as VEGF and HGF (Merino-Gonzalez et al., 2016; Pakravan et al., 2017; Han et al., 2019; Shi et al., 2019). Yang et al. showed that UCMSC microvesicles transplantation in POI mice could induce angiogenesis by activating the PI3K/Akt signaling pathway and improve ovarian function (Yang Z. et al., 2019). Sun et al. found that miR-644-5p carried by BMSC-derived exosomes inhibited the apoptosis of ovarian GCs by targeting the p53 pathway (Sun et al., 2019); Zhang et al. also found that UCMSC-derived microvesicles can inhibit the apoptosis of GSs by downregulating the expression level of caspase-3 and upregulating the ratio of Bcl-2/Bax (Zhang J. et al., 2020).

Anti-inflammatory and Immunomodulatory Effect of MSCs

POF is an autoimmune disease. Autoimmune dysfunction is one of the most important pathogeneses of POF, causing inflammatory reactions of the ovary, destroying the ultrastructure of follicular cells (such as zona pellucida damage, gap link rupture and mitochondrial swelling), causing apoptosis of ovarian cells, affecting the maturation and atresia of follicles and inducing a decline in ovarian function (Nelson, 2001; Luo et al., 2017). It has been reported that certain types of immune cells will expand in ovaries with POF and infiltrate into the ovarian tissue, indicating that they are involved in the inflammation associated with POF (van Kasteren et al., 2000; Chernyshov et al., 2001; LaMarca et al., 2010; Wang et al., 2018).

The anti-inflammatory effect is a critical mechanism by which MSCs restore ovarian function. MSCs may inhibit the activation and proliferation of lymphocytes, inhibit the secretion of proinflammatory cytokines, inhibit the function of antigen-presenting cells, and convey regulatory messages to immune cells (Zhou et al., 2019). In contrast, since the ovaries of most POF patients are in inflammatory conditions, the presence of inflammatory cytokines is also crucial for the regulation of MSC immunological and regenerative functions. Beldi et al. proved that the tumor TNF-α-TNF2R axis is necessary for MSCs to produce anti-inflammatory mediators (such as IL-10, TGFβ and NO) and sustain regenerative functions such as wound healing, complex tube formation and endothelial pro-angiogenic support (Beldi et al., 2020a; Beldi et al., 2020b). IFN-γ and MSCs have a synergistic effect on immunosuppression. They upregulate PGE2, HGF, IL-6 and TGF-1 in MSCs and induce MSCs to express IDO, promoting GC proliferation and increasing the number of follicles (Najar et al., 2016; Liang et al., 2018). Yin et al. showed that the level of proinflammatory IFN-γ increased and the level of anti-inflammatory TGF-β decreased in POF mice, whereas PMSC transplantation reversed this situation and improved ovarian function (Yin et al., 2018a). A study also showed that PMSCs increase the secretion of IL-10 by inhibiting NF-κB-mediated pro-inflammatory reactions and thus promote tissue repair (Wang et al., 2016).

Immune cells (Treg cells, NK cells, Th cells, etc.) are important pathogenic factors in several models of autoimmune diseases (Alvarez Arias et al., 2014; Gianchecchi et al., 2018; Zhang X.-M. et al., 2020; Sakaguchi et al., 2020). These results indicate that the interaction of MSCs and immune cells plays a critical role in regulating the inflammatory microenvironment of POF. Yin et al. showed that PMSC transplantation might restore the ovarian function of POF mice by balancing the ratios of Th17/Tc17 and Th17/Treg cells (Yin et al., 2018b). Lu et al. reported that the serum levels of IL-2 and IFN-γ secreted by Th1 cells increased, while IL-4 secreted by Th2 cells decreased in POF mice; however, after UMSC transplantation, the amounts of these cytokines were reversed (Lu et al., 2019). Yin et al. showed that UCMSCs...
transplantation into POF mice upregulates the ratio of CD8⁺ Treg cells, which have a typical immunosuppressive function and can reduce immune rejection (Su et al., 2014; Yin et al., 2020).

The Effect of MSCs on Oxidative Stress

Oxidative stress is a phenomenon of imbalance between the oxidative system and the antioxidative system caused by excessive ROS produced in cells. Reduction of ROS can protect the structure and function of ovarian mitochondria, increase the levels of antioxidant and antiapoptotic enzymes, and reduce apoptosis and oxidative damage of the ovary (He et al., 2018). Abumaree et al. indicated that cocultured PMSCs could reverse the destructive effect of OS on H₂O₂-treated endothelial cells and increase cell proliferation and migration (Abumaree et al., 2017). One study showed that ROS inhibit the expression and activity of TERT and induce POF (Jiang et al., 2018). MSCs can increase the production of antioxidant enzymes and inhibit ROS production through secretion of HGF, IL-6, IL-8, VEGF, BDNF and LIF and activation of the FOXO, NOQ1/MAPK, PI3K/Akt and Nrf2-ARE pathways (Amoroso et al., 2017). One study indicated that fMSCs upregulate MT1, JNK1, PCNA and AMPK levels and enhance antioxidant effects (Huang et al., 2019). Recently, it has been found that PMSC transplantation can reduce the levels of UCP-2, SOD1, reactive oxygen species and 8-hydroxydeoxyguanosine in POF rats, improving mitochondrial function in vivo, inhibiting oxidative stress and improving ovarian function (Zhang et al., 2016).

Using MSCs to treat POF is a sophisticated project. To better understand the mechanism by which MSCs improves ovarian functions, we summarized the cytokines and regulatory factors involved in the homing effect, follicular development, cell proliferation/apoptosis, angiogenesis, immunomodulation and oxidative stress processes, as shown in Table 3.

### Table 3

| Issues                      | Factors                                                                 | Function                                                                                          | References                  |
|-----------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------------------------|
| Follicular development      | TGF-β, AMH, BMPs, GDFs, TGF-β, GDF-9, BMP-15, BMP-4, BMP-7, AMH          | Promoting follicular development. Nonspecific promotion                                         | Santins et al. (2018)       |
|                             |                                                                       | Reducing GC apoptosis and promoting GC proliferation.                                              | Knight and Glister (2008)   |
|                             | TGF-β, IFN-γ, AMH                                                      | Recovering the suppressed folliculogenesis process.                                               | El-Derany et al. (2021)     |
|                             |                                                                       | Promoting follicular growth.                                                                      | Song et al. (2018)          |
| Primordial germ cells       | CD61, TGF-β, BMP4                                                     | Inhibiting GC apoptosis.                                                                         | Fang et al. (2017)          |
|                             |                                                                       | Promoting MSCs different into PGC-like cells.                                                     | Wei et al. (2016)           |
| Proliferation of GC         | AMH, VEGF, HGF, IGF-1, Bcl-2                                         | Increasing vascular diameter.                                                                    | Zhang et al. (2018)         |
|                             |                                                                       | Promoting ovarian angiogenesis.                                                                  | Fu et al. (2008)            |
| Angiogenesis                | VEGF, HGF, VEGF, IGF-1, GCSF, HGF, VEGF, FGF2                         | Improving ovarian function.                                                                      | Ding et al. (2018)          |
| Immunomodulatory effect     | IL-2, IFN-γ, IL-4                                                     | Reducing GC apoptosis.                                                                           | Sun et al. (2017)           |
| Anti-inflammatory effect    | PGE2, HGF, IL-6, TGF-1                                               | Promoting GC proliferation.                                                                      | Wang et al. (2020)          |
| Oxidative stress            | HGF, IL-6, IL-8, VEGF, BDNF, LIF                                     | Promoting vascular development and improving blood perfusion of the grafts.                     | Golocheikine et al. (2010)  |

**PERSPECTIVE**

MSCs possess multiple differentiation potentials and homing and immunomodulatory functions. They can be used as seed cells to participate in the regeneration and reconstruction of tissues and organs in various diseases, such as rheumatoid arthritis, amyotrophic lateral sclerosis, systemic lupus erythematosus and other degenerative diseases (spinal cord injury, Parkinson’s disease, Alzheimer’s disease). At present, more than ten kinds of stem cell preparations have been used to treat graft-versus-host disease (Zhao et al., 2019), acute myocardial infarction (Cho et al., 2017), osteoarthritis (Matas et al., 2019), etc. The clinical application of MSCs has brought great hope to the treatment of POF infertility and the improvement of female reproductive health, and a large number of clinical studies are actively being carried out. However, with increasing age, the number and function of MSCs decrease accordingly. The senescence of MSCs may be related to telomere shortening, DNA damage, epigenetics and immunological characteristics (Trachana et al., 2017; Wagner, 2019). At present, senescence of MSC is still the bottleneck of stem cell tissue engineering and clinical applications. Therefore, how to deeply understand the molecular mechanism of MSC senescence and delay or prevent MSC senescence efficiently through reasonable gene manipulation.
or drug intervention, has crucial practical significance and important economic value.

CONCLUSION

MSCs derived from different sources have similar curative effects in the treatment of POF through multiple mechanisms. MSCs have attractive clinical transformation and application prospects in the restoration of reproductive function in POF patients, even in older women with POF. Therefore, understanding the molecular mechanism of POF is still a key scientific problem for comprehensively and deeply evaluating the safety and effectiveness of MSC transplantation, especially the long-term impact on parents and offspring.

REFERENCES

Abumaree, M. H., Hakami, M., Abomaray, F. M., Alshabibi, M. A., Kalionis, B., Al Jumah, M. A., et al. (2017). Human Chorionic Villous Mesenchymal Stem/ Stromal Cells Modify the Effects of Oxidative Stress on Endothelial Cell Functions. Placenta 59, 74–86. doi:10.1016/j.placenta.2017.05.001

Ali, A. T. (2013). Risk Factors for Endometrial Cancer. Ceska Gynekol 78, 448–459.

Alvarez Arias, D. A., Kim, H.-J., Zhou, P., Holderrider, T. A. W., Wang, X., Dronoff, G., et al. (2014). Disruption of CD8+ Treg Activity Results in Expansion of T Follicular Helper Cells and Enhanced Antitumor Immunity. Cancer Immunol. Res. 2, 207–216. doi:10.1158/2326-6066.cir-13-0121

Amoroso, M. R., Matassa, D. S., Agliarulo, I., Avolio, R., Maddalena, F., Condelli, V., et al. (2017). Stress-Adaptive Response in Ovarian Cancer Drug Resistance. Adv. Protein Chem. Struct. Biol. 108, 163–198. doi:10.1016/bs.apcsb.2017.01.004

Badawy, A., Sohbi, M., Ahdy, M., and Abdelhafez, M. (2017). Bone Marrow Mesenchymal Stem Cell Repair of Cyclophosphamide-Induced Ovarian Insufficiency in a Mouse Model. Int. J. women Health 9, 441–447. doi:10.2147/ijwh.s134074

Bahrehbar, K., Valojerdi, M. R., Esfandiarli, F., Fathi, R., Hassan, S.-N., and Baharvand, H. (2020). Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells Improved Premature Ovarian Failure. World J. Stem Cell 12, 857–878. doi:10.4021/wjsc.v12i8.857

Bedoschi, G., Navarro, P. A., and Oktay, K. (2016). Chemotherapy-Induced Damage to Ovary: Mechanisms and Clinical Impact. Future Oncol. 12, 2333–2344. doi:10.2217/fon.16-0176

Beilmann, M., Birk, G., and Lenter, M. C. (2004). Human Primary Co-Culture Angiogenesis Assay Reveals Additive Stimulation and Different Angiogenic Properties of VEGF and HGF. Cytokine 26, 178–185. doi:10.1016/j.cytto.2004.03.003

Beldi, G., Bahrai, S., Lezin, C., Nouri Barkestani, M., Abdelgawad, M. E., Uzan, G., et al. (2020a). TNFR2 Is a Crucial Hub Controlling Mesenchymal Stem Cell Biological and Functional Properties. Front. Cell Dev. Biol. 8, 596831. doi:10.3389/fcell.2020.596831

Beldi, G., Khorsavi, M., Abdelgawad, M. E., Salomen, B. L., Uzan, G., Haouas, H., et al. (2020b). TNFR2 Signaling Pathway: An Active Immune Checkpoint for Mesenchymal Stem Cell Immunoregulatory Function. Stem Cell Res Ther 11, 281. doi:10.1186/s13238-020-01740-5

Bidarimath, M., Khalaj, K., Kridli, R. T., Kan, F. W., Koti, M., and Tayade, C. (2017). Extracellular Vesicle Mediated Intercellular Communication at the Porcine Maternal-Fetal Interface: A New Paradigm for Conceptus-Endometrial Cross-Talk. Sci. Rep. 7, 40476. doi:10.1038/srep40476

Bukovsky, A., and Caudle, M. R. (2012). Immunoregulation of Follicular Renewal, Selection, POI, and Menopause In Vivo, vs. Neo-Oogenesis In Vitro, POI and Ovarian Infertility Treatment, and a Clinical Trial. Reprod. Biol. Endocrinol. 10, 97. doi:10.1186/1477-7877-10-97

Chen, L., Guo, S., Wei, C., Li, H., Wang, H., and Xu, Y. (2018). Effect of Stem Cell Transplantation of Premature Ovarian Failure in Animal Models and Patients: A Meta-Analysis and Case Report. Exp. Ther. Med. 15, 4105–4118. doi:10.3892/etm.2018.9370

Chernyshov, V. P., Radysh, T. V., Gura, I. V., Tajarochuk, T. P., and Khominskaya, Z. B. (2001). Immune Disorders in Women with Premature Ovarian Failure in Initial Period. Am. J. Reprod. Immunol. 46, 220–225. doi:10.1046/j.1600-0897.2001.001-5.x

Cho, D. I., Kang, W. S., Hong, M. H., Kang, H. J., Kim, M. R., Kim, M. C., et al. (2017). The Optimization of Cell Therapy by Combinational Application with Apicidin-Treated Mesenchymal Stem Cells after Myocardial Infarction. Oncotarget 8, 44281–44294. doi:10.18632/oncotarget.17471

Cho, J., Kim, T.-H., Seok, J., Jun, J. H., Park, H., Kweon, M., et al. (2021). Vascular Remodeling by Placenta-Derived Mesenchymal Stem Cells Restores Ovarian Function in Ovariectomized Rat Model via the VEGF Pathway. Lab. Invest. 101, 304–317. doi:10.1038/s41374-020-00513-1

Ding, C., Zou, Q., Wang, F., Wu, H., Chen, R., Lv, J., et al. (2018). Human Amnion Mesenchymal Stem Cells Improve Ovarian Function in Natural Aging through Secreting Hepatocyte Growth Factor and Epidermal Growth Factor. Stem Cell Res Ther 9, 55. doi:10.1186/s13287-018-0781-9

Ding, L., Yan, G., Wang, B., Xu, L., Gu, Y., Yu, T., et al. (2018). Transplantation of UC-MSCs on Collagen Scaffold Activates Follicles in Dormant Ovaries of POF Patients with Long History of Infertility. Sci. China Life Sci. 61, 1554–1565. doi:10.1007/s11427-017-9277-2

Dolmans, M.-M., and Donnez, J. (2021). Fertility Preservation in Women for Medical and Social Reasons: Oocytes vs Ovarian Tissue. Best Pract. Res. Clin. Obstet. Gynaecol. 70, 63–80. doi:10.1016/j.bopobgyn.2020.06.011

Dzafic, E., Stimpfel, M., Novakovic, S., Cerovnik, P., and Virant-Klun, I. (2014). Expression of Mesenchymal Stem Cells-Related Genes and Plasticity of Aspirated Follicular Cells Obtained from Infertile Women. Biomed. Res. Int. 2014, 508216. doi:10.1155/2015/508216

El-Deiry, M. O., Said, R. S., and El-Demerdash, E. (2021). Bone Marrow-Derived Mesenchymal Stem Cells Reverse Radiotherapy-Induced Premature Ovarian Failure: Emphasis on Signal Integration of TGF-β, Wnt/β-Catenin and Hippo Pathways. Stem Cell Res Rep 17, 1429–1445. doi:10.1007/s12015-021-10135-9

Esfandiyari, S., Chugh, R. M., Park, H. S., Hobelka, E., Ulin, M., and Al-Hendy, A. (2020). Mesenchymal Stem Cells as a Bio Organ for Treatment of Female Infertility. Cells 9, 2253. doi:10.3390/cells9102253

Fang, J., Wei, Y., Lv, C., Peng, S., Zhao, S., and Hua, J. (2017). CD61 Promotes the Differentiation of Canine ADMSCs into PGC-like Cells through Modulation of TGF-β Signaling. Sci. Rep. 7, 43851. doi:10.1038/srep43851

Field, S. L., Dasgupta, T., Cummings, M., and Orsi, N. M. (2014). Cytokines in Ovarian Folliculogenesis, Oocyte Maturation and Luteinisation. Mol. Reprod. Dev. 81, 284–314. doi:10.1002/mrd.22285

Fu, X., He, Y., Xie, C., and Liu, W. (2008). Bone Marrow Mesenchymal Stem Cell Transplantation Improves Ovarian Function and Structure in Rats with...
Chemotherapy-Induced Ovarian Damage. *Cytotherapy* 10, 353–363. doi:10.1080/14653220802035926

Fu, X., He, Y., Wang, X., Peng, D., Chen, X., Li, X., et al. (2017). Overexpression of miR-21 in Stem Cells Improves Ovarian Structure and Function in Rats with Chemotherapy-Induced Ovarian Damage by Targeting PDCD4 and PTEN to Inhibit Granulosa Cell Apoptosis. *Stem Cell Res Ther* 8, 187. doi:10.1186/s13287-017-0641-z

Fu, Y. X., Ji, J., Shan, F., Li, J., and Hu, R. (2021). Human Mesenchymal Stem Cell Treatment of Premature Ovarian Failure: New Challenges and Opportunities. *Stem Cell Res Ther.* 12, 161. doi:10.1186/s13287-021-02212-0

Gahr, H., Rateb, M. A., El Sissy, M. H., Ahmed Siddiek, H., and Ali Abdelhammed Gouda, S. (2016). The Effect of Bone Marrow-Derived Mesenchymal Stem Cells on Chemotherapy Induced Ovarian Failure in Albino Rats. *Microsc. Res. Tech.* 79, 938–947. doi:10.1002/jemt.22725

Ge, W., Ma, H. G., Cheng, S. F., Sun, Y. C., Sun, L. L., Sun, X. F., et al. (2015). Differentiation of Early Germ Cells from Human Skin-Derived Stem Cells without Exogenous Gene Integration. *Sci. Rep.* 5, 13822. doi:10.1038/srep13822

Giancchecchi, E., Delfino, D. V., and Fierabracci, A. (2018). NK Cells in Autoimmune Diseases: Linking Innate and Adaptive Immune Responses. *Autoimmun. Rev.* 17, 142–154. doi:10.1016/j.autrev.2017.11.018

Golochkine, A., Tiriveedi, V., Angswamy, N., Benshoff, N., Sabarinathan, R., and Mohanakumar, T. (2010). Cooperative Signaling for Angiogenesis and Neovascularization by VEGF and HGF Following Islet Transplantation. *Transplantation* 90, 725–731. doi:10.1097/TP.0b013e3181e6a63

Gupta, S., Lodha, P., Karthick, M. S., and Tandulwadkar, S. R. (2018). Role of Autologous Bone Marrow-Derived Stem Cell Therapy for Follicular Recruitment in Premature Ovarian Insufficiency: Review of Literature and a Case Report of World’s First Baby with Autologous Stem Cell Therapy in a Perimenopausal Woman of Age 45 Year. *J. Hum. Reprod. Sci.* 11, 125–130. doi:10.4103/jhrs.JHRS_37_18

Han, Y., Ren, J., Bai, Y., Pei, X., and Han, Y. (2019). Exosomes from Hypoxia-Treated Human Adipose-Derived Mesenchymal Stem Cells Enhance Angiogenesis through VEGF/VEGF-R. *Int. J. Biochem. Cell Biol.* 109, 59–68. doi:10.1016/j.biocel.2019.01.017

He, Y., Chen, D., Yang, L., Hou, Q., Ma, H., and Xu, X. (2018). The Therapeutic Potential of Bone Marrow Mesenchymal Stem Cells in Premature Ovarian Failure. *Stem Cell Res Ther.* 9, 263. doi:10.1186/s13287-018-0008-9

Herraiz, S., Romeu, M., Buigues, A., Martínez, S., Díaz-García, C., Gómez-Seguí, I., et al. (2015). Fetal Liver Mesenchymal Stem Cells Help Restore Function to Ovaries in a Premature Ovarian Failure Mouse Model. *Plos one* 9, e98749. doi:10.1371/journal.pone.0098749

Lai, D., Wang, F., Yao, X., Zhao, Q., Wu, X., and Xiang, C. (2015). Human Endometrial Mesenchymal Stem Cells Restore Ovarian Function through Improving the Renewal of Germline Stem Cells in a Mouse Model of Premature Ovarian Failure. *J. Transl. Med.* 13, 155. doi:10.1186/s12976-015-0516-y

Lai, J. (2016). Primary Ovarian Insufficiency. *Semin. Reprod. Med.* 34, 230–234. doi:10.1055/s-0036-1585402

Lee, A. W., Wu, A. H., Wiensch, A., Mukhjerjee, B., Terry, K. L., Harris, H. R., et al. (2020). Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer. *Epidemiology* 31, 402–408. doi:10.1097/ede.0000000000001175

Li, B., Liu, W., Zhang, M., Li, N., Wu, S., Pan, S., et al. (2016). Overexpression of CD41 Promotes HU-MSC Differentiation into Male Germ-like Cells. *Cell Prolif.* 49, 36–47. doi:10.1111/cpr.12236

Li, J., Mao, Q., He, J., She, H., Zhang, Z., and Yin, C. (2017). Human Umbilical Cord Mesenchymal Stem Cells Improve the Reserve Function of Perimenopausal Ovary via a Paracrine Mechanism. *Stem Cell Res Ther.* 8 (1), 55. doi:10.1186/s13287-017-0514-5

Li, Z., Zhang, M., Tian, Y., Li, Q., and Huang, X. (2021). Mesenchymal Stem Cells in Premature Ovarian Insufficiency: Mechanisms and Prospects. *Front. Cell Dev. Biol.* 9, 718192. doi:10.3389/fcell.2021.718192

Liang, C., Jiang, E., Yao, J., Wang, M., Chen, S., Zhou, Z., et al. (2018). Interferon-γ Mediates the Immunosuppression of Bone Marrow Mesenchymal Stem Cells on T-Lymphocytes In Vitro. *Hematology* 23, 44–49. doi:10.1080/10245332.2017.1333245

Liao, Z., Liu, C., Wang, L., Sui, C., and Zhang, H. (2021). Therapeutic Role of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Female Reproductive Diseases. *Front. Endocrinol.* 12, 665645. doi:10.3389/fend.2021.665645

Lin, W., Xu, L., Zwingenberg, S., Gibon, E., Goodman, S. B., and Li, G. (2017). Mesenchymal Stem Cells Homing to Improve Bone Healing. *J. orthopaedic transl. medicine* 9, 19–27. doi:10.1038/jotm.2017.003.002

Ling, L., Feng, X., Wei, T., Wang, Y., Wang, Y., Zhang, W., et al. (2017). Effects of Low-Intensity Pulsed Ultrasound (LIPUS)-pretreated Human Amnion-Derived Mesenchymal Stem Cell (hAD-MSC) Transplantation on Primary Ovarian Insufficiency in Rats. *Stem Cell Res Ther* 8, 283. doi:10.1186/s13287-017-0739-3

Ling, L., Feng, X., Wei, T., Wang, Y., Wang, Y., Zhang, W., et al. (2019). Human Amnion-Derived Mesenchymal Stem Cell (hAD-MSC) Transplantation Improves Ovarian Function in Rats with Premature Ovarian Insufficiency (POI) at Least Partly through a Paracrine Mechanism. *Stem Cell Res Ther* 10, 46. doi:10.1186/s13287-019-1136-x

Liu, J., Zhang, Z., Zhang, Y., Li, N., Wen, Y., Cao, F., et al. (2014). Modulating and Restorative Effects of Bone Marrow-Derived Mesenchymal Stem Cells on Gisplatin Injured Ovaries in Rats. *Mol. Cell 37, 865–872.* doi:10.14348/molecells.2014.0145

Liu, S., Wang, J., Han, R., Meng, M., Wang, W., Zhao, Y., et al. (2019a). Therapeutic Effect of Transplanted Umbilical Cord Mesenchymal Stem Cells in a Cynomolgus Monkey Model of Multiple Sclerosis. *Am. J. Transl Res.* 11, 2516–2531.
Luo, R., Zhang, X., Fan, Z., Wang, Y., Yao, G., Wan, X., et al. (2019b). Human Amniotic Mesenchymal Stem Cells Improve the Follicular Microenvironment to Recover Ovarian Function in Premature Ovarian Failure Mice. *Stem Cell Res Ther* 10, 299. doi:10.1186/s13287-019-1313-y

Liu, R., Zhang, X., Fan, Z., Yao, G., Wan, X., et al. (2019c). Towards Cell Free Therapy of Premature Ovarian Insufficiency: Human Menstrual Blood Stem Cell-Derived Extracellular Vesicles Promote Angiogenesis: Potential Clinical Application. *Front. Physiol.* 7, 24. doi:10.3389/fphys.2016.00024

Matas, J., Orrego, M., Amenabar, D., Infante, C., Tapia-Limonchi, R., Cadiz, M. I., et al. (2019). Comparison of Mesenchymal Stem Cell Markers in Multiple Human Adult Stem Cells. *Int. J. Stem Cell* 7, 118–126. doi:10.15283/ijsc.2014.7.2.118

Mohamed, S. A., Shaaley, S. M., Abdelaziz, M., Brakta, S., Hill, W. D., Ismail, N., et al. (2018). Human Mesenchymal Stem Cells Partially Reverse Infertility in Chemotherapy-Induced Ovarian Failure. *Reprod. Sci.* 25, 51–63. doi:10.1177/1933719716697975

Nelson, L. (2001). Autoimmune Ovarian Failure: Comparing the Mouse Model and the Human Disease. *J. Soc. Gynecol. Invest.* 8, 555–557. doi:10.1016/s1071-5576(00)01101-6

Noory, P., Navid, S., Zanganeh, B. M., Talebi, A., Borkhani-Haghighi, M., Gholami, S., et al. (2016). Evaluation of Safety, Feasibility and Efficacy of Intra-ovarian Transplantation of Autologous Adipose Derived Mesenchymal Stromal Cells in Idiopathic Premature Ovarian Failure Patients: Non-Randomized Clinical Trial, Phase I, First in Human. *J. ovarian Res.* 14, 5. doi:10.1186/s13287-014-0048-3

Park, H. S., Chugh, R. M., Elsharoud, A., Ulin, M., Esfandyari, S., Aboaloud, A., et al. (2021). Safety of Intraovarian Injection of Human Mesenchymal Stem Cells in a Premature Ovarian Insufficiency Mouse Model. *Cell Transplant.* 30, 193687920989502. doi:10.1080/10610562.2019.1658792

Peng, J., Xiao, N., and Cheng, L. (2018). Potential Therapeutic Potential of BMSCs for Premature Ovarian Failure in Mice. *Zhong nan da Xue Xue Bao Yi Xue ban = J. Cent. South Univ. Med. Sci.* 43, 7–13. doi:10.1016/j.jsns.1672-7347.2018.01.002

Pers, Y.-M., Rackwitz, L., Ferreira, R., Pullig, O., Delfour, C., Barry, F., et al. (2016). Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial. *Stem Cell translational Med.* 5, 847–856. doi:10.5966/scm.2015-0245

Sanfins, A., Rodrigues, P., and Albertini, D. F. (2018). GDF-9 and BMP-15 Direct the Follicle Symmetry. *J. Assist. Reprod. Genet.* 35, 1741–1750. doi:10.1007/s10815-018-1268-4

Sheikhansari, G., Aghebati-Maleki, L., Nouri, M., Jadidi-Niaragh, F., and Yousefi, M. (2018). Current Approaches for the Treatment of Premature Ovarian Failure with Stem Cell Therapy. *Biomed. Pharmacother.* 102, 254–262. doi:10.1016/j.biopharma.2018.03.056

Shi, Y., Shi, H., Nomi, A., Lei-Lei, Z., Zhang, B., and Qian, H. (2019). Adipose Stem Cell-Derived Extracellular Vesicles: A New Impetus of Promoting Angiogenesis in Tissue Regeneration. *Cytotherapy* 21, 497–508. doi:10.1016/j.jcyt.2018.11.012

Song, K., Cai, H., Zhang, D., Huang, R., Sun, D., and He, Y. (2018). Effects of Adipose-Derived Mesenchymal Stem Cells Combined with Estrogen on Regulatory T Cells in Patients with Premature Ovarian Insufficiency. *Int. Immunopharmacology* 55, 257–262. doi:10.1016/j.intimp.2017.12.026

Su, J., Xie, Q., Xu, Y., Li, X. C., and Dai, Z. (2014). Role of CD8(+) Regulatory T Cells in Organ Transplantation. *Burns Trauma* 2, 18–23. doi:10.4103/2321-3868.126506

Sun, M., Wang, S., Li, Y., Yu, L., Gu, F., Wang, C., et al. (2013). Adipose-Derived Stem Cells Improved Mouse Ovary Function after Chemotherapy-Induced Ovarian Failure. *Stem Cell Res Ther* 4, 80. doi:10.1186/scrt231

Sun, L., Li, D., Song, K., Wei, J., Yao, S., Li, Z., et al. (2017). Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Protect against Cisplatin-Induced Ovarian Granulosa Cell Stress and Apoptosis In Vitro. *Sci. Rep.* 7, 2552. doi:10.1038/s41598-017-0278-x

Sun, B., Ma, Y., Wang, F., Hu, L., and Sun, Y. (2019). miR-644-5p Carried by Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Targets Regulation of P53 to Inhibit Ovarian Granulosa Cell Apoptosis. *Stem Cell Res Ther* 10, 360. doi:10.1186/s13287-019-1442-3

Taheri, M., Saki, G., Nikbakht, R., and Eftekhar, A. R. (2021). Bone Morphogenetic Protein 15 Induces Differentiation of Mesenchymal Stem Cells Derived from Human Follicular Fluid to Oocyte-Like Cell. *Cell Biol Int* 45, 127–139. doi:10.1002/cbin.11475

Takehara, Y., Yabuuchi, A., Eoee, K., Kuroda, T., Yamadera, R., Sano, C., et al. (2013). The Restorative Effects of Adipose-Derived Mesenchymal Stem Cells on Damaged Ovarian Function. *Lab. Invest.* 93, 181–193. doi:10.1038/labinvest.2012.167

Thakur, M., Feldman, G., and Puscheck, E. E. (2018). Primary Ovarian Insufficiency in Classic Galactosomia: Current Understanding and Future Research Opportunities. *J. Assist. Reprod. Genet.* 35, 3–16. doi:10.1007/s10815-017-1039-7

Trachana, V., Petrakis, S., Fotiadis, Z., Siska, E. K., Balis, V., Gonos, E. S., et al. (2017). Human Mesenchymal Stem Cells with Enhanced Telomerase Activity Acquire Resistance against Oxidative Stress-Induced Genomic Damage. *Cytotherapy* 19, 808–820. doi:10.1016/j.jcyt.2017.03.078

Trombly, D. J., Woodruff, T. K., and Mayo, K. E. (2009). Roles for Transforming Growth Factor Beta Superfamily Proteins in Early Olficoligogenesis. *Semin. Reprod. Med.* 27, 14–23. doi:10.1055/s-0028-1108006

Truman, A. M., Tilly, J. L., and Woods, D. C. (2017). Ovarian Regeneration: The Potential for Stem Cell Contribution in the Postnatal Ovary to Sustained Endocrine Function. *Mol. Cell. Endocrinol.* 445, 74–84. doi:10.1016/j.mce.2016.10.012
Yin, N., Wang, Y., Lu, X., Liu, R., Zhang, L., Zhao, W., et al. (2018b). hPMSC Treatment of Premature Ovarian Failure in Premature Ovarian Failure Mice is Associated with Change of TH17/Tc17 and TH17/Treg Cell Ratios through the PI3K/Akt Signal Pathway. Stem Cell Res Ther 9, 37. doi:10.1186/s13287-018-0772-z

Yin, N., Wu, C., Qiu, J., Zhang, Y., Bo, L., Xu, Y., et al. (2020). Protective Properties of Heme Oxygenase-1 Expressed in Umbilical Cord Mesenchymal Stem Cells Help Restore the Ovarian Function of Premature Ovarian Failure Mice through Activating the JNK/Bcl-2 Signal Pathway-Regulated Autophagy and Upregulating the Circulating of CD8+CD28+ T Cells. Stem Cell Res Ther 11, 49. doi:10.1186/s13287-019-1537-x

Yoon, S. Y., Yoon, J. A., Park, M., Shin, E.-Y., Jung, S., Lee, J. E., et al. (2020). Recovery of Ovarian Function by Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells in Cisplatin-Induced Premature Ovarian Failure in Mice. Stem Cell Res Ther 11, 255. doi:10.1186/s13287-020-01769-6

Zaher, W., Harkness, L., Jafari, A., and Kassem, M. (2014). An Update of Human Mesenchymal Stem Cell Biology and Their Clinical Uses. Arch. Toxicol. 88, 1069–1082. doi:10.1007/s00204-014-1232-8

Zhang, J., Xiong, J., Fang, L., Lu, Z., Wu, M., Shi, L., et al. (2016). The Protective Effects of Human Umbilical Cord Mesenchymal Stem Cells on Damaged Ovarian Function: A Comparative Study. Biosci. Trends 10, 265–276. doi:10.5582/bt2016.01125

Zhang, Y., Xia, X., Yan, J., Yan, L., Lu, C., Zhu, X., et al. (2017). Mesenchymal Stem Cell-Derived Angiogenin Promotes Prerodimal Follicle Survival and Angiogenesis in Transplanted Human Ovarian Tissue. Reprod. Biol. Endocrinol. 15, 18. doi:10.1186/s12958-017-0235-8

Zhang, H., Luo, Q., Lu, X., Yin, N., Zhou, D., Zhang, L., et al. (2018). Effects of hPMSCs on Granulosa Cell Apoptosis and AMH Expression and Their Role in the Restoration of Ovary Function in Premature Ovarian Failure Mice. Stem Cell Res Ther 9, 20. doi:10.1186/s13287-017-0745-5

Zhang, J., Yin, H., Jiang, H., Du, X., and Yang, Z. (2020a). The Protective Effects of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles on Cisplatin-Damaged Granulosa Cells. Taiwanese J. Obstet. Gynecol. 59, 527–533. doi:10.1016/j.tjog.2020.05.010

Zhang, X.-M., Liu, C.-Y., and Shao, Z.-H. (2020b). Advances in the Role of Helper T Cells in Autoimmune Diseases. Chin. Med. J. 133, 968–974. doi:10.1097/cmj.0000000000007478

Zhao, L., Chen, S., Yang, P., Cao, H., and Li, L. (2019). The Role of Mesenchymal Stem Cells in Hematopoietic Stem Cell Transplantation: Prevention and Treatment of Graft-Versus-Host Disease. Stem Cell Res Ther 10, 182. doi:10.1186/s13287-019-1287-9

Zheng, Q., Fu, X., Jiang, J., Zhang, N., Zou, L., Wang, W., et al. (2019). Umbilical Cord Mesenchymal Stem Cell Transplantation Prevents Chemotherapy-Induced Ovarian Failure via the NGF/TrkA Pathway in Rats. Biomed. Res. Int. 2019, 6539294. doi:10.1155/2019/6539294

Zhou, Y., Yamamoto, Y., Xiao, Z., and Ochiya, T. (2019). The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity. J. Clin. Med. 8, 1025. doi:10.3390/jcm8071025

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the editors, the reviewers and the producers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Liu, Yu, Yang, Li and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
| Term                | Definition                                      |
|---------------------|------------------------------------------------|
| ADMSC               | adipose-derived stem cells                     |
| AFMSC               | amniotic fluid mesenchymal stem cells          |
| akt                 | protein kinase B                               |
| AMH                 | anti-mullerian hormone                         |
| AMPK                | adenosine 5’-monophosphate (AMP)-activated protein kinase |
| AMSC                | amniotic mesenchymal stem cells                |
| ARE                 | antioxidant response element                   |
| AZPAb               | anti-Zona pellucida antibody                   |
| Bax                 | Bcl-2 associated X protein                     |
| Bcl-2               | B-cell lymphoma-2                              |
| b-FGF               | basic fibroblast growth factor                 |
| BDNF                | brain-derived neurotrophic factor              |
| Bim                 | Bcl-2 interacting mediator of cell death       |
| BMP                 | bone morphogenetic protein                    |
| BMSC                | bone marrow stem cells                         |
| CD                  | cluster of differentiation                     |
| EGF                 | epidermal growth factorepidermal growth factor |
| E2                  | estrogen                                       |
| EGF                 | epidermal growth factorepidermal growth factor |
| FGF                 | fibroblast growth factor                       |
| FOXO                | forkhead box O                                 |
| FSH                 | follicle stimulating hormone                   |
| FSHR                | follicle stimulating hormone receptor          |
| fst                 | homo sapiens follistatin                      |
| GC                  | ovarian granulosa cells                        |
| GC                  | ovarian granulosa cells                        |
| GCSF                | granulocyte colony stimulating factor          |
| Gdf                 | growth differentiation factor                  |
| HGF                 | hepatocyte growth factor                       |
| HOVEC               | human ovarian endothelial cell                 |
| HRT                 | hormone replacement therapy                   |
| IDO                 | indoleamine 2,3-dioxxygenase                   |
| IGF-1               | insulin-like growth factors-1                  |
| IFN-γ               | interferon γ                                   |
| IRAK1               | interleukin 1 receptor associated Kinase 1     |
| IL                  | interleukin-10                                 |
| JNK1                | jun n-terminal kinase1                         |
| LH                  | luteinizing hormone                            |
| LIF                 | interleukin 6 family cytokine                  |
| MAPK                | mitogen-activated protein kinase               |
| MCP                 | monocyte chemotactic protein                   |
| Mensc               | menstrual-derived stem cell                   |
| MSC                 | mesenchymal stem cells                         |
| MVs                 | microvesicles                                  |
| MT1                 | melatonin receptor 1                           |
| Nanos3              | nanos C2HC-type Zinc finger 3                  |
| NF-κB               | nuclear factor kappa-light-chain-enhancer of activated B cells |
| NK                  | natural killer cell                            |
| Nobox               | NOBOX oogenesis homeobox                       |
| NO                  | nitric oxide                                   |
| NOQ1                | NAD(P)H quinone dehydrogenase 1                |
| Nrf2                | NF-E2-related factor 2                         |
| OGCs                | ovarian granulosa cells                        |
| PARP                | poly ADP-ribose polymerase                     |
| PCNA                | proliferating cell nuclear antigen             |
| PDCD4               | programmed cell death 4                       |
| PDMSC               | placenta-derived mesenchymal stem cells        |
| PGF                 | placental growth factor                        |
| PGE2                | prostaglandin E2                               |
| PGC                 | primordial germ cell                           |
| PMSC                | placenta-derived mesenchymal stem cell         |
| POF                 | premature ovarian failure                      |
| PTEN                | phosphatase and tensin homolog                 |
| PI3K                | phosphatidylinositol-3-kinase                  |
| ROS                 | reactive oxygen species                        |
| SC                  | stem cell                                      |
| SOD1                | superoxide dismutase 1                         |
| TERT                | telomerase reverse transcriptase                |
| TGF                 | transforming growth factor                     |
| th                  | helper T cell                                  |
| TNF-α               | tumor necrosis factor-α                        |
| TRAF632             | receptor associated factor 632                 |
| UCMSC               | umbilical cord mesenchymal stem cells          |
| UCMSC               | umbilical cord mesenchymal stem cells          |
| UCP-2               | uncoupling protein-2                           |
| VEGF                | vascular endothelial growth factor             |
| VEGFR               | vascular endothelial growth factor             |